Pharmacokinetic and Pharmacodynamic Characterization of Semaglutide in Humans: A Review of the Current State of Knowledge

Semaglutide is a synthetic peptide that mimics the action of the naturally occurring hormone GLP-1. It was first approved by the FDA in 2017 for the treatment of type 2 diabetes and has since been investigated for its potential benefits in weight management and other indications. The pharmacokinetic profile of semaglutide has been extensively studied, with results showing that it is characterized by a rapid absorption, a peak plasma concentration reached within 2-3 hours after administration, and a prolonged elimination half-life of approximately 13 days. The pharmacodynamic effects of semaglutide have also been well characterized, with results showing that it increases glucose-dependent insulin secretion, reduces glucagon levels, and slows gastric emptying. Clinical trials have demonstrated the efficacy and safety of semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes and obesity. However, further research is needed to fully understand the mechanisms of action and optimal dosing regimens for this medication.